Immunwork’s proprietary technology mainly relates to two major sets of inventions. One set pertains to the molecular platforms for configuring various pharmaceutical molecules, and the other set to the novel combinations of targeting and effector elements used in configuring specific T-E molecules. We believe that our technology can provide solutions for constructing improved antibody drug conjugates (ADCs), bispecific antibodies, multivalent antibodies, and other classes of pharmaceuticals.
Our proprietary core technology is built on “multi-arm linker units” and various protein engineering methods. A linker unit’s linking arms can be covalently conjugated with small molecules, peptides, proteins, antibody fragments, e.g., single-chain variable fragments (scFvs). T-E pharmaceutical molecules can be configured using one, two, or three multi-arm linker units to combine with different functional components. Most T-E molecules are about the size of IgG (150 kDa) or smaller; some are in the range of 150-210 kDa.
The concept and practice of “precision medicine”is becoming a major trend in pharmaceutical development. The modular configuration of T-E pharmaceuticals offers versatility in designing personalized therapeutics according to individual patient’s clinical conditions, e.g. the profiles of targetable antigens on patient’s tumor cells, or the HLA-A, B, and C allotypes on the transplanted organ.
